drugset / Trial / NCT04842045
Pilot RECAP Study in Healthy Volunteers
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the RECAP Study Program is to investigate the role played by conscious experience in the antidepressant effects of the psychedelic agent psilocybin. This pilot dosing study (PILOT RECAP) is designed to determine the optimal dose of midazolam that allows a psychedelic experience to occur while inducing amnesia for the experience. This is an essential step required for subsequent evaluation of the role of memory for the psychedelic experience in the antidepressant effects of psilocybin in the full RECAP study.
Timeline
- Start
- 2021-05-21
- Primary completion
- 2022-11-17
- Completion
- 2022-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midazolam | Small molecule | — | Intravenous |
| Subject | Psilocybin | Other / unclassified | 25 mg | — |